Skip to main content

Table 1 Patient characteristics stratified by baseline circulating tumor cell value

From: Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

Variable Overall CTC < 5 CTC ≥ 5 Pvalue
All patients 235 (100) 141 (60) 94 (40) -
Age (years) 53 (23 to 82) 53 (28 to 82) 53 (23 to 81) 0.451
Follow-up (months) 18 (1 to 65) 20 (1 to 65) 18 (3 to 61) -
HR+/HER-2 normal 130 (55.3) 74 (52.5) 56 (59.6) 0.349
HR+/HER-2 overexpressed/amplified 21 (8.9) 15 (10.6) 6 (6.4) 0.352
HR-/HER-2 overexpressed/amplified 22 (9.4) 13 (9.2) 9 (9.6) 1.0
Triple receptor negative 62 (26.4) 39 (27.7) 23 (24.4) 0.651
Visceral metastases 140 (59.6) 80 (56.7) 60 (63.8) 0.342
Number of metastatic sites     
   1 85 (36.2) 61 (43.3) 24 (25.5) 0.011*
   2 65 (27.6) 38 (26.9) 27 (28.8)  
   ≥ 3 85 (36.2) 42 (29.8) 43 (45.7)  
  1. Data presented as n (%) or median (range). CTC, circulating tumor cell; HER-2, human epidermal growth factor receptor-2; HR+, estrogen receptor-positive and/or progesterone receptor-positive; HR-, both estrogen receptor-negative and progesterone receptor-negative. * Statistical significant value.